Short-Term Mitigation Steps During the Iohexol Contrast Shortage: A Single Institution ’s Approach

In the United States, over 40% of CT examinations use iodinated contrast agents (ICAs) for better visualization and assessment of pathophysiological processes [1]. Recent COVID-19 related work slowdowns in Shanghai, China, have affected operations of General Electric (GE) factories and reduced production of Omnipaque (iohexol, GE Healthcare, Milwaukee, Wisconsin) contrast agents, with estimates that the factory will remain at reduced capacity through the end of June 2022, and shortages potentially persisting through the middle to end of the summer [2].
Source: Journal of the American College of Radiology : JACR - Category: Radiology Authors: Tags: Special Commentary (Opinion) Source Type: research